What Makes Verona Pharma plc (VRNA) a Good Investment?

Soumya Eswaran

Thu, May 8, 2025, 7:54 AM 3 min read

Buckley Capital Advisors, an concern absorption company, released its archetypal 4th 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The money returned -0.5% (net) successful the 4th compared to -7.7% instrumentality for iShares Russell 2000 Value Index and -9.5% instrumentality for the iShares Russell 2000 Index. In the quarter, Donald Trump’s assertive tariff plans accrued economical uncertainty. Although tariffs straight interaction little than 5% of the portfolio, the steadfast was prepared for this situation. However, the wide selling of stocks affected it significantly. The steadfast focuses connected the fundamentally beardown companies careless of the economical environment. In addition, you tin cheque the fund’s apical 5 holdings to find its champion picks for 2025.

In its first-quarter 2025 capitalist letter, Buckley Capital Advisors highlighted stocks specified arsenic Verona Pharma plc (NASDAQ:VRNA). Verona Pharma plc (NASDAQ:VRNA) is simply a biopharmaceutical company. The one-month instrumentality of Verona Pharma plc (NASDAQ:VRNA) was 23.24%, and its shares gained 350.61% of their worth implicit the past 52 weeks. On May 7, 2025, Verona Pharma plc (NASDAQ:VRNA) banal closed astatine $69.14 per stock with a marketplace capitalization of $8.699 billion.

Buckley Capital Advisors stated the pursuing regarding Verona Pharma plc (NASDAQ:VRNA) successful its Q1 2025 capitalist letter:

"Verona Pharma plc (NASDAQ:VRNA) has developed a merchandise called ensifentrine (Ohtuvayre), a bronchodilator and anti-inflammatory cause for attraction attraction of COPD. COPD, much commonly known arsenic smoker’s lung, is caused by contamination oregon smoking. Diagnosis of COPD lowers beingness expectancy by astir 6 years. Symptoms of COPD are shortness of breath, cough, wheezing, and sputum. COPD affects astir 400 cardinal radical worldwide, with 8.6m radical treated successful the United States.

A diligent successful a clinic, taking a medicine dose from a nebulizer to dainty a respiratory disease.

Verona Pharma plc (NASDAQ:VRNA) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge money portfolios held Verona Pharma plc (NASDAQ:VRNA) astatine the extremity of the 4th quarter, compared to 25 successful the 3rd quarter. Verona Pharma plc (NASDAQ:VRNA) reported revenue of $76.3 cardinal successful the archetypal quarter, which was successful enactment with anterior quarters. While we admit the imaginable of Verona Pharma plc (NASDAQ:VRNA) arsenic an investment, our condemnation lies successful the content that AI stocks clasp greater committedness for delivering higher returns, and doing truthful wrong a shorter timeframe. If you are looking for an AI banal that is arsenic promising arsenic NVIDIA but that trades astatine little than 5 times its earnings, cheque retired our study astir the cheapest AI stock.